Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14

Journal of Clinical Oncology

Volumn 29, Issue 29, 2011, Pages 3869-3876

  Pritchard, Kathleen I ^a   Shepherd, Lois E ^b   Chapman, Judith Anne W ^b   Norris, Brian D ^h   Cantin, Jacques ⁱ   Goss, Paul E ^k   Dent, Susan F ^c   Walde, David ^d   Vandenberg, Ted A ^e   Findlay, Brian ^f   O'Reilly, Susan E ^h   Wilson, Carolyn F ^b   Han, Lei ^b   Piura, Ettie ^j   Whelan, Timothy J ^g   Pollak, Michael N ^j  

^a UNIVERSITY OF TORONTO   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d Sault Area Hospitals   (Canada)

^e London Regional Cancer Program   (United Kingdom)

^f Systeme de sante de Niagara   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^j MCGILL UNIVERSITY   (Canada)

^k MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; C PEPTIDE; OCTREOTIDE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TAMOXIFEN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RISK; CANCER SIZE; CANCER STAGING; CHOLECYSTECTOMY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GALLBLADDER DISEASE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; C-PEPTIDE; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; OCTREOTIDE; POSTMENOPAUSE; QUALITY OF LIFE; TAMOXIFEN; TREATMENT OUTCOME; VITAMIN D;

EID: 80053932300     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.7006     Document Type: Article

References (29)

1. Weckbecker G, Raulf F, Stolz B, et al: Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 60:245-264, 1993 (Pubitemid 24117378)
2. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): A randomized controlled trial. Lancet 369:559-570, 2007
3. Lee MT, Liebow C, Kamer AR, et al: Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc Natl Acad Sci U S A 88:1656-1660, 1991 (Pubitemid 21916284)
4. Buscail L, Delesque N, Estève J, et al: Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A 91:2315-2319, 1994 (Pubitemid 24092094)
5. Lamberts SW: Octreotide. N Engl J Med 334:246-254, 1996
6. van Eijck CH, Krenning EP, Bootsma A, et al: Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343:640-643, 1994 (Pubitemid 24087809)
7. Setyono-Han B, Henkelman MS, Foekens JA, et al: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47:1566-1570, 1987 (Pubitemid 17044484)
8. Pollak M, Polychronakos C, Guyda H: Somatostatin analogue SMS 201-995 reduces serum IGF-1 levels in patients with neoplasms potentially dependent on IGF-1. Anticancer Res 9:889-892, 1989 (Pubitemid 19266323)
9. Pollak M: Insulin and insulin-like growth factor signaling in neoplasia. Nat Cancer Rev 8:915-928, 2008
10. Pollak M, Costantino J, Polychronakos C, et al: Effect of tamoxifen on serum insulin-like growth factor 1 levels in stage 1 breast cancer patients. J Natl Cancer Inst 82:1693-1697, 1990
11. Pollak M, Ingle J, Suman VJ, et al: Enhancement of tamoxifen-induced suppression of serum IGF-1 levels in metastatic breast cancer patients by coadministration of the somatostatin-analogue octreotide. Presented at the 87th Annual Meeting of the American Association of Cancer Research, Washington, DC, April 20-24, 1996 (abstr 1167)
12. Morere JF, Cour V, Breau JL, et al: Stabilizing effect of BIM 23014, a long-acting somatostatin analog, in 30 cases of advanced breast cancer: A phase II study. Proc Am Soc Clin Oncol 8:47, 1989 (abstr 179)
13. Vennin P, Peyrat JP, Bonneterre J, et al: Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. Anticancer Res 9:153-156, 1989 (Pubitemid 19096210)
14. Stolfi R, Parisi AM, Natoli C, et al: Advanced breast cancer: Response to somatostatin. Anticancer Res 10:203-204, 1990 (Pubitemid 20155737)
15. Cannata D, Boccardo F, Canobbio L: Somatuline plus tamoxifen in post-menopausal breast cancer patients. Ann Oncol 3:76, 1992 (suppl 5)
16. Weckbecker G, Tolcsvai L, Stolz B, et al: Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas. Cancer Res 54:6334-6337, 1994
17. Soran A, Nesbitt L, Mamounas EP, et al: Centralized medical monitoring in phase III clinical trials: The National Surgical Adjuvant Breast and Bowel Project (NSABP) experience. http://www.nsabp.pitt.edu/NSABP-Bibliography.asp
18. Pollak M, Pritchard KI, Whelan T, et al: The NCIC CTG MA.14 experience with the gallbladder toxicity of octreotide pamoate (Oncolar) in a post-menopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer. Eur J Cancer 38:S93, 2002 (suppl 3)
19. Gail M, Simon R: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41:361-372, 1985
20. Gordon Lan KK, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
21. Piura E, Chapman JW, Lipton A, et al: Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. J Clin Oncol 27:15s, 2009 (suppl; abstr 534)
22. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002 (Pubitemid 34032594)
23. Costantino JP, Kuller LH, Ives DG, et al: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89:776-782, 1997 (Pubitemid 27242278)
24. Chlebowski RT, Johnson KC, Kooperberg C, et al: Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100:1581-1591, 2008
25. Goodwin PJ, Ennis M, Pritchard KI, et al: Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27:3757-3763, 2009
26. Zakikhani M, Blouin MJ, Piura E, et al: Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123:271-279, 2010
27. Pollak M: Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res 3:1060-1065, 2010
28. Goodwin PJ, Stambolic V, Lemieux J, et al: Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126:215-220, 2011
29. Algire C, Amrein L, Bazile M, et al: Diet and LKB1 expression interact to determine sensitivity to antineoplastic effects of metformin in vivo. Oncogene 30:1174-1182, 2011